<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05062005</url>
  </required_header>
  <id_info>
    <org_study_id>NCICCRTvCRT</org_study_id>
    <nct_id>NCT05062005</nct_id>
  </id_info>
  <brief_title>ICCRT vs. CRT for Locally Advanced Nasopharyngeal Carcinoma</brief_title>
  <official_title>Induction Chemotherapy+Chemoradiotherapy vs. Chemoradiotherapy for Locally Advanced Nasopharyngeal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>First Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>First Affiliated Hospital, Sun Yat-Sen University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is a multi-center phase III clinical trial. The purpose of this trial is to&#xD;
      explore whether concurrent chemoradiotherapy is not inferior to induction chemotherapy&#xD;
      combined with concurrent chemoradiotherapy in patients with locally advanced nasopharyngeal&#xD;
      carcinoma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">September 22, 2021</start_date>
  <completion_date type="Anticipated">August 31, 2027</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2027</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>FFS (Failure-free Survival)</measure>
    <time_frame>3 year</time_frame>
    <description>Defined as the time from randomization to tumor recurrence, distant metastasis, or death due to any reason, whichever occurs first. Patients who withdraw or who are lost to follow-up will be censored at the date last known to be alive and progression free. Patients not having an event will be censored at the date last seen alive.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>OS (Overall Survival)</measure>
    <time_frame>3 year</time_frame>
    <description>Defined as the time from randomization until death from any cause. Patients who withdraw or who are lost to follow-up will be censored at the date last known to be alive. Patients remaining alive throughout the duration of the study will have their survival time censored on the date last seen alive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LRFS (Locoregional Recurrence-free Survival)</measure>
    <time_frame>3 year</time_frame>
    <description>Defined as the time from randomization to local or regional recurrence. Patients who withdraw or who are lost to follow-up will be censored at the date last known to be alive and recurrence free. Patients not having an event will be censored at the date last seen alive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DMFS (Distant Metastasis-free Survival)</measure>
    <time_frame>3 year</time_frame>
    <description>Defined as the time of randomization to the appearance of distant metastasis. Patients who withdraw or who are lost to follow-up will be censored at the date last known to be alive and metastasis free. Patients not having an event will be censored at the date last seen alive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AE (Adverse events)</measure>
    <time_frame>3 year</time_frame>
    <description>Adverse events during the treatment period will be assessed according to the Common Terminology Criteria for Adverse Events (CTCAE, version 5.0). Late AE of radiotherapy will be assessed according to RTOG criteria.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">447</enrollment>
  <condition>Locally Advanced Nasopharyngeal Carcinoma</condition>
  <arm_group>
    <arm_group_label>Induction Chemotherapy+Chemoradiotherapy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Chemoradiotherapy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Induction Chemotherapy</intervention_name>
    <description>Induction regimens: TP (docetaxel 75 mg/m²; cisplatin 75 mg/m²) Q3w, TPF (docetaxel 60 mg/m²; cisplatin 60 mg/m²; 5-fluorouracil 600-750 mg/m² per day, continuous intravenous infusion d1-5) Q3w, or GP (gemcitabine: 1000 mg/m2 d1, d8; cisplatin 80 mg/m2) Q3w.</description>
    <arm_group_label>Induction Chemotherapy+Chemoradiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Concurrent Chemotherapy</intervention_name>
    <description>Cisplatin 100 mg/m², Q3w.</description>
    <arm_group_label>Chemoradiotherapy</arm_group_label>
    <arm_group_label>Induction Chemotherapy+Chemoradiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Definitive Radiotherapy</intervention_name>
    <description>For all patients, the prescribed dose is 66-70 Gy (once a day, 5 times a week).</description>
    <arm_group_label>Chemoradiotherapy</arm_group_label>
    <arm_group_label>Induction Chemotherapy+Chemoradiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18-65 years old;&#xD;
&#xD;
          2. Pathologically confirmed non-keratinizing nasopharyngeal carcinoma;&#xD;
&#xD;
          3. Stage T3-4N0-1 (according to the UICC/AJCC 8th);&#xD;
&#xD;
          4. No distant metastasis;&#xD;
&#xD;
          5. Have not received anti-cancer treatment in the past;&#xD;
&#xD;
          6. ECOG (Eastern Cooperative Oncology Group of the United States): 0-1;&#xD;
&#xD;
          7. Adequate hematologic, hepatic and renal function.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. The purpose of treatment is palliative;&#xD;
&#xD;
          2. Diagnosed with other malignant tumors at the same time;&#xD;
&#xD;
          3. Malignant tumor history;&#xD;
&#xD;
          4. Pregnancy or breastfeeding, or expect to become pregnant during the clinical trial&#xD;
             period;&#xD;
&#xD;
          5. Combined serious illness.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Shuang Wu, PHD</last_name>
    <phone>+862087755766</phone>
    <email>wush77@mail.sysu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guang Dong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shuang Wu, PHD</last_name>
      <phone>+862087755766</phone>
      <email>wush77@mail.sysu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 7, 2021</study_first_submitted>
  <study_first_submitted_qc>September 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 30, 2021</study_first_posted>
  <last_update_submitted>September 21, 2021</last_update_submitted>
  <last_update_submitted_qc>September 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>First Affiliated Hospital, Sun Yat-Sen University</investigator_affiliation>
    <investigator_full_name>Chen Yong</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Carcinoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

